-
Added 3 Fanconi anemia patients treated with briquilimab before stem cell transplant
-
All six Fanconi anemia patients treated with briquilimab achieved complete donor engraftment and complete blood cell recovery, and briquilimab was well tolerated.
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) announced the launch of briquilimab, a novel antibody therapy targeting c-Kit (CD117). A biotechnology company focused on the development of Additional positive Phase 1b on Brikilimab as a conditioning agent in the treatment of Fanconi anemia (FA) to address mast cell-mediated diseases such as chronic spontaneous urticaria (CSU) and chronic induced urticaria (CIndU) /2a phase data announced.
This data was presented at the 2024 Stanford Medical Center Curative and Curative Medicine Symposium on March 13, 2024 in Palo Alto, California.
An ongoing investigator-initiated phase 1b/2a clinical trial is evaluating conditioning therapy, including intravenous briquilimab, as a potential treatment for FA patients with bone marrow failure. Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six treated patients achieving complete donor engraftment and Achieved blood cell recovery.
“We continue to be encouraged by the results of Stanford Medicine’s Phase 1b/2a study in Fanconi anemia, which raises the possibility that briquilimab may serve as an important component of nontoxic conditioning therapy for stem cell transplantation. “It's showing sex,” Chief Edwin Tucker said. Jasper's medical officer. “We would like to thank our collaborators at Stanford Medicine for their efforts in evaluating briquilimab in this vulnerable patient population.”
About Briquilimab
Brikilimab (formerly JSP191) is a targeted non-glycosylation drug that blocks stem cell factor binding to the cell surface receptor c-Kit (also known as CD117) and inhibits receptor-mediated signaling. It is a monoclonal antibody. This inhibition disrupts important survival signals, depletes mast cells through apoptosis, and eliminates the root cause of inflammatory responses in mast cell-driven diseases such as chronic urticaria. Dr. Jasper is currently conducting a clinical study of briquilimab as a treatment for patients with CSU or CIndU. Brikilimab is currently under clinical investigation as a treatment for patients with LR-MDS and as a modulator for cell and gene therapy for rare diseases. To date, briquilimab has demonstrated efficacy and safety profiles in more than 145 treated participants and healthy volunteers, including patients with severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), and myelodysplasia. It has yielded clinical outcomes as a conditioning agent in plastic syndrome syndrome (MDS), FA. , sickle cell disease (SCD).
About Fanconi anemia
Fanconi anemia (FA) is a rare but serious blood disorder that prevents the bone marrow from producing enough new red blood cells. This disorder may also cause the bone marrow to produce abnormal blood cells. FA usually begins at birth or in early childhood between the ages of 5 and 10 years. Ultimately, it can lead to serious complications such as bone marrow failure and severe aplastic anemia. Cancers such as acute AML and MDS are also considered complications. Treatment may include blood transfusions and drugs to increase red blood cell production, but currently hematopoietic stem cell transplantation (HSCT) is the only treatment available.
About Phase 1/2 clinical trial (NCT04784052)
The Stanford University-sponsored, physician-led Phase 1/2 trial is an open-label clinical trial evaluating briquilimab as a potential treatment for FA patients with bone marrow failure (BMF) who require allogeneic transplantation. . This regimen, which utilizes briquilimab, eliminates the need for busulfan chemotherapy and total body radiation. Participants in FA with BMF received TCRαβ+ T cell/CD19+ B cell-depleted hematopoietic grafts from 10/10 unrelated donors, 9/10 unrelated donors, or haploidentical familial donors. undergo allogeneic HCT. Brikilimab at a dose of 0.6 mg/kg is administered in combination with standard FA doses of antithymocyte globulin (ATG), cyclophosphamide, fludarabine, and rituximab as lymphodepletion. Key outcomes include safety, efficacy, and engraftment success.
About Jasper
Jasper is developing briquilimab, a monoclonal antibody targeting c-Kit (CD117), as a treatment for chronic mast and stem cell diseases, including chronic urticaria and low-to-intermediate-risk MDS, and as a conditioning agent for stem cell transplants. A clinical-stage biotechnology company. We deal with rare diseases such as SCD, FA, and SCID. To date, briquilimab has demonstrated efficacy and safety profile in over 145 treated participants and healthy volunteers, and clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia, MDS, FA, and SCD. is obtained. For more information, please visit www.jaspertherapeutics.com.
Forward-looking statements
Certain statements contained in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include words such as “believes,” “may,” “will,” “estimates,” “continues,” “anticipates,” “intends,” “expects,” “should”, “will”, “plan”, “anticipate”, “could”, “likely”, “seek”, “future”, “outlook”, and future events. or similar expressions that predict or suggest trends or are not historical statements. These forward-looking statements include statements regarding the potential of briquilimab, its safety profile, and potential to serve as a key ingredient, including its potential as a conditioning agent in the treatment of FA and FA patients with bone marrow failure. but not limited to. A non-toxic conditioning regimen for stem cell transplantation and its potential to address mast cell-derived diseases such as CSU and CIndU. These statements are based on various assumptions and Jasper's current expectations, whether or not identified in this press release, and are not predictive of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as guarantees, guarantees, predictions, or conclusive statements of fact or probabilities, and investors should not rely on them. should not be relied upon as such. Many actual events and circumstances are beyond Jasper's control. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions. the risk that potential product candidates developed by Jasper may not proceed through clinical development or obtain necessary regulatory approvals within the expected schedule or at all; the risk that the safety, efficacy or other product characteristics described or envisioned in this press release may not be confirmed in clinical trials; the risk that Jasper will be unable to successfully market or lose market acceptance of its product candidates; the risk that the results of previous studies may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or be successfully commercialized; Patients' willingness to try new treatments and physicians' willingness to prescribe these treatments. the impact of competition on Jasper's business; the risk that third parties on which Jasper relies for laboratory, clinical development, manufacturing or other critical services may not perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain may be adversely affected by the effects of a health epidemic; the risk that Jasper will be unable to obtain and maintain adequate intellectual property protection for its investigational products or that it will infringe on the intellectual property protection of others; and as shown from time to time in Jasper's filings with the SEC, including his Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. and other risks and uncertainties that may arise. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from those suggested by these forward-looking statements. Although Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's valuation after the date of this press release. Therefore, you should not place undue reliance on forward-looking statements.
contact address:
Joyce Allaire (Investor)
Life science advisor
617-435-6602
jallaire@lifesciadvisors.com
Alex Gray (Investor)
jasper therapeutics
650-549-1454
agray@jaspertherapeutics.com
Lauren Walker (Media)
real chemistry
646-564-2156
lbarbiero@realchemistry.com